The Institute of Cancer Research

Dr Udai Banerji is currently an honorary consultant in Medical Oncology at the Royal Marsden, London, UK.   He is Deputy Head of the Drug Development Unit, which has a portfolio of over 30 phase I trials, and he is involved in running a number of these trials.  His interests include the discovery and applications of HSP90, PI3K, AKT and mTOR inhibitors.  He has been a principal investigator of over 25 phase I studies and has been a sub-investigator on over 100 phase I studies.

In addition to Phase 1 trials, Dr Banerji’s independent laboratory interests include the use of pharmacodynamic biomarkers.  He heads the Clinical  PD Biomarker Group at The Institute of Cancer Research, which focuses on the quantification of biomarkers in normal tissue (platelet-rich plasma, peripheral blood mononuclear cells and hair follicles) and tumour tissue to be used as pharmacodynamic biomarkers in Phase I studies.  He also runs a laboratory team with interests in understanding dynamic signaling networks to devise interesting drug combinations.